ONCAlert | 2018 ASCO Annual Meeting

The Impact of Angiotensin System Inhibitors on Outcomes in Patients with mRCC

Rana R. McKay, MD
Published Online: 7:30 PM, Thu January 30, 2014
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who used angiotensin system inhibitors (ASI). Read more about this trial > >

Clinical Pearls

  • This study evaluated OS in ASI users versus nonusers in patients with mRCC
  • OS was 27 months compared to 17 months (ASI users vs nonusers, respectively; hazard ratio=1.2)
  • In a subset analysis stratified by types of therapy for mRCC (including VEGF-targeted therapy, mTOR-targeted therapy, and IFN-α therapy), the only statistically significant OS benefit was seen in patients receiving VEGF-targeted therapy

<<< Back to the GU 2014 conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.